Ignite Creation Date:
2024-05-06 @ 2:41 AM
Last Modification Date:
2024-10-26 @ 11:22 AM
Study NCT ID:
NCT02100046
Status:
COMPLETED
Last Update Posted:
2018-04-04
First Post:
2014-03-20
Brief Title:
Assessment of the Effectiveness of Ethosuximide in the Treatment of Peripheral Neuropathic Pain
Sponsor:
University Hospital Clermont-Ferrand
Organization:
University Hospital Clermont-Ferrand
Study Overview
Official Title:
Assessment of the Effectiveness of Ethosuximide in the Treatment of Peripheral Neuropathic Pain
Status:
COMPLETED
Status Verified Date:
2018-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
EDONOT
Brief Summary:
Currently it is established that the voltage-gated calcium channels modulate pain perception due to an influence on the neuronal transmission and excitability In the past attention has focused on the modulation of high voltage activated calcium channel More recently scientific interest has proven to the low voltage activated calcium channel also called T-type channels The data from the literature show significant involvement of these channels in the physiology of nociception and pathophysiology of acute and chronic pain Moreover in several animal pain models acute neuropathic inflammatory T-type channels inhibition alleviates painful behaviours
Analgesics treatments available in clinic are ineffective in some patients with chronic pain neuropathic inflammatory and often induce deleterious side effects Thus the clinical use of selective inhibitors of T-type channels could not only help the development of new therapies for the treatment of neuropathic pain prevalence 5-8 but also have a pharmaco-economic impact due to the low selling price of their inhibitor currently available Zarontin
The purpose of this study is to assess the effectiveness of ethosuximide Zarontin on the pain symptoms and quality of life in patients with peripheral neuropathic pain compared to a control group
Analgesics treatments available in clinic are ineffective in some patients with chronic pain neuropathic inflammatory and often induce deleterious side effects Thus the clinical use of selective inhibitors of T-type channels could not only help the development of new therapies for the treatment of neuropathic pain prevalence 5-8 but also have a pharmaco-economic impact due to the low selling price of their inhibitor currently available Zarontin
The purpose of this study is to assess the effectiveness of ethosuximide Zarontin on the pain symptoms and quality of life in patients with peripheral neuropathic pain compared to a control group
Detailed Description:
This is a multicentre parallel-group double-blind randomised clinical trial comparing ethosuximide and inactive control for the treatment of peripheral neuropathic pain assessed by numerical rating scale and quality of life questionnaire
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2013-004801-26 | None | None | None |